Clinical Trials · NCT06584916
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 376
- Start date
- Sep 2024
- Locations
- 29 sites, United States, Puerto Rico
- Primary endpoint
- Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5